Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Eduardo Arce Parellada, General Manager at Sanofi Pasteur Mexico until March 2017, explains the positive impact that the vaccine against Dengue could generate for the national health system and showcases…
Gabriela Báez, Chief Commercial Officer of Up Pharma, elaborates on the company’s unique business model that supports small to medium sized pharmaceutical and preventative health companies in entering the Mexican…
Dominik Bacher, founder and CEO at Bacher Zoppi, explains the latest changes in the commercialization stage of the healthcare industry and showcases the value proposition of Bacher Zoppi to successfully…
José Antonio Garcia, CEO of Vensi, describes how the company’s unique service model is redefining how healthcare institutions approach the purchasing of medical equipment, while detailing the strategic significance of…
With an impressive achievement of growing the novel “flexible solutions” business unit by an astounding 50 percent in his first year of spearheading the region, Ricardo Uribe, Covance Mexico’s Director…
In charge of transforming the Monterrey-based family business of dermatological distribution into a Mexican corporate success story, Carlos de Kruyff, shares some of his most pertinent insights on the industry.…
Aimed to ignite a paradigm shift away from the current traditional distributor model, Salumedic’s Managing Director, Gabriel Tagle, shares the novel business concept with zeal and sharp business acumen. He…
The founder and Managing Director of Global Health Intelligence (GHI), Guillaume Corpart highlights the value of competitive intelligence for medical device companies looking to either enter emerging healthcare markets in…
Aristides Torres, CEO at Laboratorios Vanquish, explains how the company has evolved during the last five years to serve both the public and private markets and why they have focused…
Sergio Olivares, managing director at Olivares, explains the TPP’s impact on the Mexican pharmaceutical industry’s dynamism and Olivares’ business proposal as a one-stop shop solution to fulfill all its current…
“Equipment is not everything that GE can contribute with!” – The CEO and President of GE Healthcare’s Mexican Unit elaborates on how GE provides added value to its customers by…
Arturo Rodríguez Jacob, CEO at Infinite Clinical Research (ICR) and president of the national association of CROs (ACROM), explains what make Mexico the regional clinical research hub and showcases how…
See our Cookie Privacy Policy Here
